Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[F-18]MeFAMP
- Development stage
- Phase 1
- Lead developer
- University of Alabama at Birmingham
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
[F-18]MeFAMP is a radioconjugate composed of the non-natural amino acid (R)-3-fluoro-2-methyl-2-(methylamino)propanoic acid (MeFAMP) radiolabeled with the positron-emitting isotope fluorine-18. It functions as a system A amino acid transport substrate for positron emission tomography (PET) imaging of primary and metastatic brain tumors. The tracer has shown promising results in preclinical models for imaging brain tumors and other malignancies.
- Other names
- fluorine F 18-labeled MeFAMP3-[18F]fluoro-2-methyl-2-N-(methyl amino) propanoic acid
02
Targets
SNAT2 (Sodium-coupled neutral amino acid transporter 2)Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on [F-18]MeFAMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [F-18]MeFAMP.